ABS20191007_0001
Hypertrophic Obstructive Cardiomyopathy
Long-Term Outcomes of Alcohol Septal Ablation in HOCM Patients Receiving the Same Dose of Ethanol
Maksim Kashtanov1, Anastasiya Rzannikova1, Sergey Chernyshev1, Lev Kardapoltsev1, Anton Kazakov1, Dariya Goncharova1, Valentina Kochmasheva1, Eduard Idov1
Sverdlovsk Regional Hospital N1, Russian Federation1
Background:
Emphasis in the study was placed on the assessment of long-term results of alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy (HOCM), with all of them receiving a 3 ml ethanol dose. Generally, ethanol (0.5 - 3 ml) is infused depending on a septal artery width or interventricular septum (IVS) thickness during alcohol septal ablation. We injected 3ml of ethanol without regard to IVS thickness, perforator width in all our cases.
Methods:
Between 2000 and 2017, 150 HOCM patients (78 males, 72 females) underwent alcohol septal ablation procedures. In all cases we intentionally used one and the same dose of ethanol (3ml). The median of age was 52 (interquartile range: 41-60) years.
Results:
The median follow-up was 71 (interquartile range: 36-110) months. Hospital mortality was 0.67% (one patient died of sepsis). Perioperative high-grade atrioventricular blocks required permanent pacemaker implantations - 18 (12%). Long-term survival rates were as follows: 95.1% (95%CI:92.7-97.5), 85.8% (95%CI:83.7%-87.0%) ¬Ú 81.7% (95%CI:79.7%-83.7%) at 5-, 10- and 15-year follow-up, respectively. One-sample log-rank test revealed no significant differences in 15-year survival rates between the alcohol septal ablation cohort and age- and sex-matched Russian population.
Conclusion:
Alcohol septal ablation with the same (3 ml) ethanol dose is safe and efficient. Survival rates after alcohol septal ablation are comparable with those in age- and sex-matched general Russian population.
like off

Leave Comments